US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

12.25 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand ↗
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... 
Via Benzinga
Topics Intellectual Property
News headline image
Dr. Reddy’s Q3 & 9M FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr Reddy's Laboratories: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Is NYSE:RDY suited for quality investing? ↗
Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. 
Via Chartmill
News headline image
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Should you consider NYSE:RDY for quality investing? ↗
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
News headline image
Dr. Reddy’s Q2 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. ↗
Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors. 
Via Chartmill
News headline image
Chart Of The Day: What's Cooking At Dr. Reddy's Lab ↗
100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha 
Via Talk Markets
News headline image
Top 5 Health Care Stocks That May Fall Off A Cliff ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Q1 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Why Are Journey Medical Shares Trading Lower Today? ↗
Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release... 
Via Benzinga
News headline image
Drugmaker GSK: Becoming a Healthier Value Stock
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit. 
Via MarketBeat
Topics Lawsuit
News headline image
Why Are Journey Medical Shares Trading Higher Today ↗
Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the  
Via Benzinga
News headline image
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
The 3 Most Undervalued Value Stocks to Buy in June 2023 ↗
One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June. 
Via InvestorPlace
News headline image
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
News headline image
Dr. Reddy’s Q4 & FY23 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Why Aditxt Shares Are Surging Today ↗
Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases. 
Via Benzinga
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
By David Willey, Benzinga 
Via TheNewswire.com
< Previous 1 2 3 4 5 6 7 8 9 Next >